The radiosensitizing activity of the SMAC-mimetic, Debio 1143, is TNFα-mediated in head and neck squamous cell carcinoma.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Radiotherapy and Oncology

• Publication date

  2015-09-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.radonc.2015.05.017PMID 26096848
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Safety, pharmacokinetics, and pharmacodynamic properties of oral DEBIO1143 (AT-406) in patients with advanced cancer: results of a first-in-man study

  2015cited by this paper
• Cancer-Specific Mortality and Competing Mortality in Patients with Head and Neck Squamous Cell Carcinoma: A Competing Risk Analysis

  2014cited by this paper
• Necroptosis: Molecular Signalling and Translational Implications

  2014cited by this paper
• International head and neck cancer epidemiology consortium: Update no. 14

  2014cited by this paper
• Debio 1143, an antagonist of multiple inhibitor-of-apoptosis proteins, activates apoptosis and enhances radiosensitization of non-small cell lung cancer cells in vitro.

  2014cited by this paper
• Smac mimetic primes apoptosis-resistant acute myeloid leukaemia cells for cytarabine-induced cell death by triggering necroptosis.

  2014cited by this paper
• Inhibitor of apoptosis (IAP) proteins-modulators of cell death and inflammation.

  2013cited by this paper
• Smac mimetic and demethylating agents synergistically trigger cell death in acute myeloid leukemia cells and overcome apoptosis resistance by inducing necroptosis

  2013cited by this paper
• Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): an open-label phase 3 randomised trial.

  2012cited by this paper
• Targeting IAP proteins for therapeutic intervention in cancer

  2012cited by this paper
• Smac-mimetic compound SM-164 induces radiosensitization in breast cancer cells through activation of caspases and induction of apoptosis

  2012cited by this paper
• AT-406, an orally active antagonist of multiple inhibitor of apoptosis proteins, inhibits progression of human ovarian cancer

  2012cited by this paper
• Novel promising IAP antagonist on the horizon for clinical translation.

  2012cited by this paper
• Modulation of immune signalling by inhibitors of apoptosis.

  2012cited by this paper
• Radiosensitization of Head and Neck Squamous Cell Carcinoma by a SMAC-Mimetic Compound, SM-164, Requires Activation of Caspases

  2011cited by this paper
• A small-molecule IAP inhibitor overcomes resistance to cytotoxic therapies in malignant gliomas in vitro and in vivo.

  2011cited by this paper
• Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): a comprehensive analysis by tumour site.

  2011cited by this paper
• A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment.

  2011cited by this paper
• In vitro and in vivo radiosensitization of colorectal cancer HT-29 cells by the smac mimetic JP-1201.

  2010cited by this paper
• IAP inhibitors enhance co-stimulation to promote tumor immunity

  2010cited by this paper
• Death through a tragedy: mitotic catastrophe

  2008cited by this paper
• Expression and prognostic significance of IAP-family genes in human cancers and myeloid leukemias.

  2000cited by this paper

• Comparing and combining xevinapant with ATR and PARP inhibition for the radiosensitization of HPV-negative HNSCC cells

  2026cites this paper
• Xevinapant plus Chemoradiotherapy Negatively Sculpts the Tumor-Immune Microenvironment in Head and Neck Cancer

  2025cites this paper
• Evolving Neoadjuvant, Adjuvant, and Concurrent Systemic Therapy Strategies in Head and Neck Squamous Carcinoma.

  2025cites this paper
• Recent progress in the treatment of locally advanced head and neck squamous cell carcinomas

  2025cites this paper
• Inhibiting NHEJ in HNSCC cell lines by the ligase IV inhibitor SCR130 has limited radiosensitizing effects

  2025cites this paper
• Xevinapant plus avelumab in advanced solid tumours, with a dose expansion in advanced non-small-cell lung cancer: exploratory biomarker, safety and efficacy analyses from an open-label, nonrandomised phase Ib study

  2025cites this paper
• Revolutionizing cancer therapy: Monoclonal antibodies in radiosensitization

  2025cites this paper
• Metabolic pathway-based subtypes associate glycan biosynthesis and treatment response in head and neck cancer

  2024cites this paper
• Xevinapant combined with pembrolizumab in patients with advanced, pretreated colorectal and pancreatic cancer: results of the phase 1b/2 CATRIPCA trial.

  2024cites this paper
• Physician Perspectives on the Management of Patients with Resected High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck Who Are Ineligible to Receive Cisplatin: A Podcast

  2024cites this paper
• High TNF and NF-κB Pathway Dependency Are Associated with AZD5582 Sensitivity in OSCC via CASP8-Dependent Apoptosis

  2024cites this paper
• Multifaceted Evaluation of Inhibitors of Anti-Apoptotic Proteins in Head and Neck Cancer: Insights from In Vitro, In Vivo, and Clinical Studies (Review)

  2024cites this paper
• cIAP-2 protein is upregulated by human papillomavirus in oropharyngeal cancers: role in radioresistance in vitro

  2024cites this paper
• Study on the sensitizing effect of SM-1 combined with irradiation on head and neck squamous cell carcinoma

  2024cites this paper
• Evasion of apoptosis and treatment resistance in squamous cell carcinoma of the head and neck.

  2024cites this paper
• Xevinapant plus radiotherapy in resected, high-risk, cisplatin-ineligible LA SCCHN: the phase III XRay Vision study design.

  2024cites this paper
• Extended follow-up of a phase 2 trial of xevinapant plus chemoradiotherapy in high-risk locally advanced squamous cell carcinoma of the head and neck: a randomised clinical trial.

  2023cites this paper
• Precision medicine in nasopharyngeal carcinoma: comprehensive review of past, present, and future prospect

  2023cites this paper
• Model‐Informed Selection of the Recommended Phase III Dose of the Inhibitor of Apoptosis Protein Inhibitor, Xevinapant, in Combination with Cisplatin and Concurrent Radiotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck

  2023cites this paper
• Evolving role of novel radiosensitizers and immune checkpoint inhibitors in (chemo)radiotherapy of locally advanced head and neck squamous cell carcinoma.

  2023cites this paper
• Managing cisplatin-ineligible patients with resected, high-risk, locally advanced squamous cell carcinoma of the head and neck: Is there a standard of care?

  2023cites this paper
• The Effect of Xevinapant Combined with Ionizing Radiation on HNSCC and Normal Tissue Cells and the Impact of Xevinapant on Its Targeted Proteins cIAP1 and XIAP

  2023cites this paper
• The expanding role of IAP antagonists for the treatment of head and neck cancer

  2023cites this paper
• Advances in molecular targeted therapies to increase efficacy of (chemo)radiation therapy

  2023cites this paper
• Good Radiosensitizer Hunting.

  2023cites this paper
• Xevinapant or placebo plus chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck: TrilynX phase III study design.

  2022cites this paper
• Inhibiting the inhibitors: Development of the IAP inhibitor xevinapant for the treatment of locally advanced squamous cell carcinoma of the head and neck

  2022influential citation
• Clinical Trial Development in TP53-Mutated Locally Advanced and Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma.

  2022cites this paper
• A Review of the Current Impact of Inhibitors of Apoptosis Proteins and Their Repression in Cancer

  2022cites this paper
• Potential for reversing miR-634-mediated cytoprotective processes to improve efficacy of chemotherapy against oral squamous cell carcinoma

  2022cites this paper
• cIAP1/2 are involved in the radiosensitizing effect of birinapant on NSCLC cell line in vitro

  2021cites this paper
• Exploratory window‐of‐opportunity trial to investigate the tumor pharmacokinetics/pharmacodynamics of the IAP antagonist Debio 1143 in patients with head and neck cancer

  2021cites this paper
• Combining radiation to EGFR and Bcl-2 blockade: a new approach to target cancer stem cells in head and neck squamous cell carcinoma

  2021cites this paper
• Proinflammatory Signaling Pathways and Genomic Signatures in Head and Neck Cancers

  2021cites this paper
• Regulation of NFκB Signalling by Ubiquitination: A Potential Therapeutic Target in Head and Neck Squamous Cell Carcinoma?

  2020influential citation
• The effect of DEBIO 1143 usage alone or in combination with Tamoxifen on estrogen receptor positive breast cancer cell lines.

  2020cites this paper
• ASTX660, an antagonist of cIAP1/2 and XIAP, increases antigen processing machinery and can enhance radiation-induced immunogenic cell death in preclinical models of head and neck cancer

  2020cites this paper
• The inhibitor of apoptosis proteins antagonist Debio 1143 promotes the PD-1 blockade-mediated HIV load reduction in blood and tissues of humanized mice

  2020cites this paper
• The Immuno-Modulatory Effects of Inhibitor of Apoptosis Protein Antagonists in Cancer Immunotherapy

  2020cites this paper
• The Mitochondrion as an Emerging Therapeutic Target in Cancer.

  2020cites this paper
• Debio 1143 and high-dose cisplatin chemoradiotherapy in high-risk locoregionally advanced squamous cell carcinoma of the head and neck: a double-blind, multicentre, randomised, phase 2 study.

  2020cites this paper
• ANTP‐SmacN7 fusion peptide‐induced radiosensitization in A549 cells and its potential mechanisms

  2020cites this paper
• Phase I Trial of Debio 1143, an Antagonist of Inhibitor of Apoptosis Proteins, Combined with Cisplatin Chemoradiotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck

  2020cites this paper
• Future Therapeutic Directions for Smac-Mimetics

  2020cites this paper
• Inhibitor of Apoptosis Protein (IAP) Antagonists in Anticancer Agent Discovery: Current Status and Perspectives.

  2019cites this paper
• Peptide functionalised gold nanorods for the selective eradication of target cells using photothermal therapy

  2019cites this paper
• Investigation of the pathophysiology of granulosa cell tumours of the ovary

  2019cites this paper
• Dual Antagonist of cIAP/XIAP ASTX660 Sensitizes HPV− and HPV+ Head and Neck Cancers to TNFα, TRAIL, and Radiation Therapy

  2019cites this paper
• LCL161, a SMAC-mimetic, Preferentially Radiosensitizes Human Papillomavirus–negative Head and Neck Squamous Cell Carcinoma

  2019cites this paper
• Antagonist of cIAP1/2 and XIAP enhances anti-tumor immunity when combined with radiation and PD-1 blockade in a syngeneic model of head and neck cancer

  2018cites this paper
• Apoptosis-sensitizing activity of birinapant in head and neck squamous cell carcinoma cell lines.

  2018cites this paper
• Nuclear Imaging Study of the Pharmacodynamic Effects of Debio 1143, an Antagonist of Multiple Inhibitor of Apoptosis Proteins (IAPs), in a Triple-Negative Breast Cancer Model

  2018cites this paper
• Smac mimetics as novel promising modulators of apoptosis in the treatment of breast cancer

  2018cites this paper
• SMAC Mimetic Debio 1143 and Ablative Radiation Therapy Synergize to Enhance Antitumor Immunity against Lung Cancer

  2018cites this paper
• Investigating the adverse effects of novel tumour-specific IAP antagonists

  2017cites this paper
• Inducing death in tumor cells: roles of the inhibitor of apoptosis proteins

  2017cites this paper
• Effects of 12C6+ heavy ion beam irradiation on the p53 signaling pathway in HepG2 liver cancer cells

  2017cites this paper
• Genomics and advances towards precision medicine for head and neck squamous cell carcinoma

  2017cites this paper
• Molecular radiation biology/oncology and its impact on preclinical and clinical research in radiotherapy.

  2017cites this paper
• Molecular determinants of radiosensitivity in normal and tumor tissue: A bioinformatic approach.

  2017cites this paper
• Overcoming chemotherapy drug resistance by targeting inhibitors of apoptosis proteins (IAPs)

  2017cites this paper
• Therapeutic Small Molecules Target Inhibitor of Apoptosis Proteins in Cancers with Deregulation of Extrinsic and Intrinsic Cell Death Pathways

  2016cites this paper
• Genomic insights into head and neck cancer

  2016cites this paper
• Cutting-edge research in basic and translational radiation biology/oncology reflections from the 14th International Wolfsberg Meeting on Molecular Radiation Biology/Oncology 2015.

  2015cites this paper